nach oben

Hepatology International

Erschienen in:

17.04.2020 | Editorial

Stopping oral antiviral treatment to cure chronic hepatitis B, is it in sight?

verfasst von: Rong Fan, Jinlin Hou

Erschienen in: Hepatology International | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

The treatment of chronic hepatitis B (CHB) patients has evolved dramatically over the past two decades. Currently, oral nucleos(t)ide analogues (NA) with potent viral suppression and a high genetic barrier to resistance, i.e., entecavir, tenofovir disoproxil and tenofovir alafenamide, are recommended as first-line antivirals. Long-term NA treatment can suppress hepatitis B virus (HBV) replication, reverse liver fibrosis, and reduce the risk of hepatocellular carcinoma (HCC) [1]. …

Hou JL, Zhao W, Lee C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol 2020;18:457–467

Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629–636

Berg T, Simon KG, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients—FINITE study. J Hepatol 2017;67:918–924CrossRef

Jeng W-J, Chen Y-C, Chien R-N, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B. Hepatology 2018;68:425–434CrossRef

Liem KS, Fung S, Wong DK, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut 2019;68:2206–2213CrossRef

Buti M, Wong DK, Gane E, et al. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol 2019;4:296–304CrossRef

Chen C-H, Hu T-H, Wang J-H, et al. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int 2019. https://doi.org/10.1007/s12072-019-09991-y CrossRefPubMedPubMedCentral

Lim SG, Amarapurkar DN, Chan HL-Y, et al. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int 2015;9:43–51CrossRef

Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 2016;63:1481–1492CrossRef

10.

Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res 2014;44 Suppl S1:1–58

11.

Hsu YC, Nguyen MH, Mo LR, et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther 2019;49:107–115CrossRef

12.

Fan R, Zhou B, Xu M, et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin Gastroenterol Hepatol 2020;18:719–727

13.

Fan R, Peng J, Xie Q, et al. Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients. J Infect Dis 2020. https://doi.org/10.1093/infdis/jiaa136 CrossRefPubMedPubMedCentral

14.

World Health Organization. Combating Hepatitis B and C to reach elimination by 2030. Available from: https://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf. Accessed Nov 2016

Titel: Stopping oral antiviral treatment to cure chronic hepatitis B, is it in sight?
verfasst von: Rong Fan
Jinlin Hou
Publikationsdatum: 17.04.2020
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 3/2020
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-020-10039-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Stopping oral antiviral treatment to cure chronic hepatitis B, is it in sight?

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer

Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy

Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management

Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis

Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma

Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin